tbuckley/cabot-search huggingface dataset:
PTU-071 Frequency and outcomes associated with rapid viral response in individuals on pegylated interferon and ribavirin therapy: Abstract PTU-071
Authors: J M Tait, D Knight, J F Dillon
Journal: Gut (2010)

<h3>Introduction</h3> Studies have shown that attaining a rapid viral response (RVR) (PCR negative after 4 weeks of interferon and ribavirin therapy) is emerging as a robust predictor of sustained viral response (SVR) to treatment. We started routinely measuring HCV PCR after 4 weeks of treatment in April 2007. The aim of this study was to evaluate the frequency and outcomes associated with RVR in clinical practice. <h3>Methods</h3> A prospective study was carried out on all individuals who had received interferon and ribavirin therapy in our centre between April 2007 and November 2009. <h3>Results</h3> A total of 164 individuals were included in the study. 111 (67.7%) were male. The age range was 19 to 77 with a mean of 43.8 years. 67 (40.8%) were genotype 1, 7 (4.2%) genotype 2, 88 (53.6%) genotype 3, and 2 (1.2%) genotype 4. At end week 4, 80/164 (48.7%) had a RVR, of these 22% were genotype 1/4 and 67.7% were 2/3. Of the individuals who did not achieve a RVR, 49 (29.9%) had more than a 2-log drop in viral load, 28 (17%) had less than a 2-log drop and 7 (4.2%) stopped treatment before 4 weeks. 36 individuals are still in treatment. In 128 cases where treatment has ended 75% (96/128) completed treatment. The following analysis focuses on the 96 individuals who are 6 months post treatment. Of the 39 had achieved an RVR (6 genotype 1/4. 33 genotype 2/3), three stopped treatment early (between 4 and 12 weeks) and 35 (97.2%) who subsequently completed treatment achieved a SVR. 21 (84%) who achieved more than a 2-log drop at 4 weeks and completed treatment had SVR and 3 (42.8%) who had less than a 2-log drop had SVR (Abstract 071). <h3>Conclusion</h3> This study shows that 48.7% of individuals achieved a RVR. The frequency of RVR was significantly altered by genotype. This study confirms that the result of viral load at 4 weeks is very predictive of an SVR if individuals adhere to treatment, with 97.2% of individuals with RVR who completed treatment achieving a SVR. The numbers in this study are small however the results can be used to motivate individuals with RVR or more than a 2 log drop in viral load at 4 weeks to complete their full course of treatment.
Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report
Authors: Pierre-Edouard Debureaux, Flore Sicre de Fontbrune, Carmem M. S. Bonfim, Jean-Hugues Dalle, Nimrod Buchbinder, Yves Bertrand, Cecile Renard, Edouard Forcade, Juliana Fernandes, Alexis Talbot, Ricardo Pasquini, Jean Soulier, Thierry Leblanc, Gerard Socie, Regis Peffault de Latour
Journal: Blood (2019)
Mechanisms of proapoptotic properties of curcumin in chronic and acute myeloid leukemia
Authors: Myung-Ju Ahn, Sung-Soo Yoon, Eunkyung Bae, Kwang-Sung Ahn
Journal: Cancer Research (2004)

4121  Curcumin, a yellow coloring agent from turmeric (Curcuma longa Linn, Zingiberaceae), possesses strong antimutagenic and anticarcinogenic activities. However, molecular mechanisms underlying its anticancer activities remain to be defined in both chronic (CML) and acute myeloid leukemia (AML). To investigate whether curcumin induces apoptosis, pAkt, Bcl-2 family, Caspase 3 and cell cycle proteins including p53, Erk, P21, cyclin D and pRb were examined for their expression by western analysis. CML cell line (K562) and AML cell line (CCRF-SM) were treated with 50μM curcumin. Curcumin caused dose-dependent apoptosis in both CML and AML cells. Apoptosis was preceded by the sequential dephosphorylation of Akt, down-regulation of the anti-apoptotic Bcl-2 and activation of caspase 3. When the cells were pre-treated with cyclosporin A, dephosphorylation of Akt markedly decreased and cell viability increased. These indicated that curcumin induced apoptosis by inactivation the Akt-related cell survival pathway, providing a new mechanism for curcumin-induced cytotoxicity. Also, the expression of P21 and p53 were elevated and that of cyclin D decreased with curcumin treatment. Our study indicated that curcumin could induce apoptosis by disturbing cell cycle progression in both chronic and acute myeloid leukemia.
Phase I study of gemcitabine and cisplatin followed by pemetrexed and gemcitabine in patients with metastatic transitional cell carcinoma of the urothelium: Preliminary results
Authors: T. E. Hutson, S. Vukelja, S. Nicol, K. E. Hood, A. Delgado, D. Ilegbodu, W. R. Berry
Journal: Journal of Clinical Oncology (2006)

14550 Background: Pemetrexed has activity as a single agent and combined with gemcitabine (G) in platinum refractory metastatic urothelial cancer. The tolerability and activity of this new multi-targeted antifolate combined with standard platinum-based therapy is unknown. This Phase I multicenter trial was conducted in patients (pts) with metastatic TCC to determine the maximum tolerated dose (MTD) of G and cisplatin (C) followed by pemetrexed (P) and G. Methods: Cohorts of 3 to 6 pts were treated with escalating doses of G+C followed by P+G: Dose Level 0 -G+C (800+60 mg/m 2 ) Day 1 and P+G (400+800 mg/m 2 ) on Day 15; Dose Level I -G+C (800+70 mg/m 2 )/P+G (400+800 mg/m 2 ); Dose Level II -G+C (1000+70 mg/m 2 )/P+G (400+1000 mg/m 2 ); Dose Level III -G+C (1000+70 mg/m 2 )/P+G (500+1000 mg/m 2 ) in a 28-day cycle. Pts received a maximum of 6 cycles of therapy; and all pts received folic acid and vitamin B 12 supplements. The 3+3 standard Phase I escalation rule was used to establish the MTD. Results: A total of 10 pts have registered, 1 pt received only 1 dose and was replaced, and 9 have been treated: 3 at Dose Level 0 and 6 at Dose Level I. Of these 10 pts, 40% had Karnofsky PS of 100, and the median age was 68 years (range 58–82). One pt had a confirmed CR after 2 cycles, 1 pt at Dose Level I had a PR and received all 6 cycles, 6 pts did not finish treatment (4 pts due to toxicity and 2 pts due to PD), 1 pt at Dose Level I is continuing on therapy. Dose-limiting toxicity occurred in 2 pts at Dose Level I and included Grade 3–4 febrile neutropenia, pulmonary embolism, and diarrhea. The MTD of this triplet is Dose Level I, and the recommended Phase II dose (RP2D) is Dose Level 0. Patient accrual is continuing to further define toxicity at the RP2D. Conclusion: The addition of pemetrexed to standard gemcitabine and cisplatin as initial therapy for metastatic urothelial cancer is feasible. Toxicity of this triplet has been moderate. A Phase II trial is planned to determine the response rate, duration of response, TTP, time to treatment failure, and survival. Supported by Eli Lilly and Company, Indianapolis, IN [Table: see text]
Administration of Plerixafor in Poor Mobilizers Allows Mobilization of Haematopoietic Progenitors: Clonogenic Potential and Engraftment Analysis
Authors: Laura Pezzetti, Giambattista Bertani, Liliana Intropido, Tiziana Lamacchia, Mariateresa Pugliano, Elisabetta Bice Volpato, Elisa Zucchetti, Giovanni Grillo, Roberto Cairoli
Journal: Blood (2019)
Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML
Authors: Amanda R. Leonti, Laura Pardo, Todd A. Alonzo, Robert B. Gerbing, Lisa Eidenschink Brodersen, Rhonda E. Ries, Jenny L. Smith, Quy Le, Richard Aplenc, E. Anders Kolb, John L. Magnani, William E. Fogler, Michael R. Loken, Soheil Meshinchi
Journal: Blood (2019)
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
Authors: Sant Chawla, Jean-Yves Blay, Piotr Rutkowski, Axel Le Cesne, Peter Reichardt, Hans Gelderblom, Robert J Grimer, Edwin Choy, Keith Skubitz, Leanne Seeger, Scott M Schuetze, Robert Henshaw, Tian Dai, Danielle Jandial, Emanuela Palmerini
Journal: The Lancet Oncology (2019)
The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Authors: Yang Liu, Shuangtao Zhao, Changying Jiang, Yixin Yao, Kelley Paige Murfin, Hadley Grundman, Liang Zhang, Krystle Nomie, Linghua Wang, Michael Wang
Journal: Blood (2019)
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
Authors: Niranjan J. Sathianathen, Samantha Koschel, Isaac A. Thangasamy, Jiasian Teh, Omar Alghazo, Georgiana Butcher, Harriet Howard, Jada Kapoor, Nathan Lawrentschuk, Shankar Siva, Arun Azad, Ben Tran, Damien Bolton, Declan G. Murphy
Journal: European Urology (2019)
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen
Authors: Uday Popat, Rima M. Saliba, Rohtesh S. Mehta, Amanda L. Olson, Julianne Chen, Christina Ganesh, Gabriela Rondon, Glenda Woodworth, Becky McMullin, Amin M. Alousi, Paolo Anderlini, Gheath Alatrash, Qaiser Bashir, Stefan O. Ciurea, Chitra Hosing, Jin S Im, Partow Kebriaei, Issa F. Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Samer Srour, Katayoun Rezvani, Muzaffar H. Qazilbash, Jeffrey J. Molldrem, Elizabeth J. Shpall, Borje S Andersson, Richard E. Champlin
Journal: Blood (2019)
Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails
Authors: Sariya Wongsaengsak, Somedeb Ball, Nuvneet Khandelwal, Alay Tikue, Arunee Motes, Nusrat Jahan, Kyaw Zin Thein, Lukman Tijani
Journal: Blood (2019)
Mutations in Triple-Negative Patients with Myeloproliferative Neoplasms
Authors: Maria Carolina Costa Melo Svidnicki, Paula De Melo Campos, Moisés Alves Ferreira Filho, Caio Augusto Leme Fujiura, Tetsuichi Yoshizato, Hideki Makishima, Seishi Ogawa, Sara T Olalla Saad
Journal: Blood (2019)
Megaloblastic anaemia associated with sulphasalazine treatment.
Authors: M Bateson
Journal: BMJ (1977)

an observation not previously made") Hillyer5 wrote in 1971: "the results suggest that auto- immune and/or localised in vivo antigen-antibody reactions may play a significant role in the patho- genesis of schistosomiasis...." In 1930 Muller and Stender reported a similar case.6 EEG, EMG, and spinal cord evoked response studies of the reported case must be most relevant.It is regrettable that these studies were not mentioned in the article.The treatment given to this patient (niridazole 25 mg/kg twice daily for 14 days and then prednisolone 10 mg three times daily, reducing to 5 mg daily after one week) must be con- sidered too little and too late.Why were hycanthone and higher doses of prednisolone not tried in this utmost neurological emergency?What could have been the relative or absolute contraindications ?F HASSIB London NW2
Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Authors: Elias Jabbour, Kathryn G. Roberts, Koji Sasaki, Yaqi Zhao, Chunxu Qu, Zhaohui Gu, Nitin Jain, Keyur P. Patel, Farhad Ravandi, Nicholas J. Short, Guillermo Garcia-Manero, Rebecca Garris, Steven Kornblau, Marina Y Konopleva, Charles G. Mullighan, Hagop M. Kantarjian
Journal: Blood (2019)
Divergent Selection and Primary Gene Flow Shape Incipient Speciation of a Riparian Tree on Hawaii Island
Authors: Jae Young Choi, Michael Purugganan, Elizabeth A Stacy
Journal: Molecular Biology and Evolution (2019)

Abstract A long-standing goal of evolutionary biology is to understand the mechanisms underlying the formation of species. Of particular interest is whether or not speciation can occur in the presence of gene flow and without a period of physical isolation. Here, we investigated this process within Hawaiian Metrosideros, a hypervariable and highly dispersible woody species complex that dominates the Hawaiian Islands in continuous stands. Specifically, we investigated the origin of Metrosideros polymorpha var. newellii (newellii), a riparian ecotype endemic to Hawaii Island that is purportedly derived from the archipelago-wide M. polymorpha var. glaberrima (glaberrima). Disruptive selection across a sharp forest-riparian ecotone contributes to the isolation of these varieties and is a likely driver of newellii’s origin. We examined genome-wide variation of 42 trees from Hawaii Island and older islands. Results revealed a split between glaberrima and newellii within the past 0.3–1.2 My. Admixture was extensive between lineages within Hawaii Island and between islands, but introgression from populations on older islands (i.e., secondary gene flow) did not appear to contribute to the emergence of newellii. In contrast, recurrent gene flow (i.e., primary gene flow) between glaberrima and newellii contributed to the formation of genomic islands of elevated absolute and relative divergence. These regions were enriched for genes with regulatory functions as well as for signals of positive selection, especially in newellii, consistent with divergent selection underlying their formation. In sum, our results support riparian newellii as a rare case of incipient ecological speciation with primary gene flow in trees.
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia
Authors: Yumeng Zhang, Hannah H Asghari, Onyee Chan, Dasom Lee, Martine Extermann, Najla Al Ali, Yehuda E. Deutsch, Eric Padron, Andrew T Kuykendall, Alan F. List, Hugo F. Fernandez, Jeffrey E. Lancet, Rami S. Komrokji, David A Sallman, Chetasi Talati, Kendra L. Sweet
Journal: Blood (2019)
Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia
Authors: Amany R. Keruakous, Jennifer Holter Chakrabarty, Sarah Ann Schmidt, Mohamad O. Khawandanah, George Selby, Carrie Yuen
Journal: Blood (2019)
Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT
Authors: Marie Robin, Liesbeth C. de Wreede, Eric Padron, Junfeng Wang, Sheree Hazelaar, Dietrich W. Beelen, Pierre Fenaux, Martin Bornhäuser, Nicolaus Kroeger, Aziz Nazha, Aleksandar Radujkovic, Raajit K. Rampal, Jürgen Finke, Rami S. Komrokji, Victoria Potter, Sally Killick, Didier Blaise, Eric Solary, Angus Broom, Guillermo Garcia-Manero, Vittorio Rizzoli, Mrinal M Patnaik, Francesco Onida, Ibrahim Yakoub-Agha, Raphael Itzykson
Journal: Blood (2019)
Middle East Respiratory Syndrome (MERS) Infection in Hematological and Oncological Patients: A Case Series from a Tertiary Care Center in Saudi Arabia
Authors: Ahmed Alaskar, Mohammed Bosaeed, Hina Rehan, May Anne Mendoza, Bader Alahmari, Adel Othman, Ayman Alhejazi, Khadega Abuelgasim, Moussab Damlaj, Mohsen Alzahrani, Giamal Gmati, Hind Salama, Mostafah Abolfotouh, Naila Shaheen
Journal: Blood (2019)
Hydroxyurea Reverses Dysfunctional Ubiquitin-Proteasomal System in Sickle CELL Disease and Suppresses Posttranslational Alterations in Hemoglobin and CELL Membranes
Authors: Swee Lay Thein, Arun S Shet, Michael Brad Strader, Fanato Meng, Michael Heaven, Jana Sirsendu, Abdu Alayash
Journal: Blood (2019)
Granulomatous Myositis Showing Fluctuating “Leopard-Man” Sign
Authors: Masamichi Koyama, Takashi Terauchi, Mitsuru Koizumi, Yoshiya Sugiura
Journal: Clinical Nuclear Medicine (2019)

Abstract A 57-year-old woman with a history of uterine endometrial carcinoma underwent PET/CT examinations for initial staging and posttreatment survey. Multiple patchy accumulations were noted in the muscles, particularly in both thighs. These accumulations resolved spontaneously 6 months after the follow-up examination. However, 3.5 years after the surgery, the multiple patchy accumulations reappeared in the muscle of the upper and lower extremities showing an increase in signal intensity from previous examination. A biopsy of the right thigh revealed epithelioid cell granuloma without necrosis. We therefore consider that this case might be “idiopathic” granulomatous myositis.
NIMG-37. PREDICTING SEIZURE IN GLIOMA PATIENTS USING A RANDOM FOREST CLASSIFIER TRAINED ON SEX-SPECIFIC AND MIXED COHORTS
Authors: Aditya Khurana, Sandra Johnston, Paula Whitmire, Sara Ranjbar, Akanksha Sharma, Andrea Hawkins-Daarud, Joshua Rubin, Alyx Porter, Peter D Canoll, Kathleen Egan, Leland Hu, Maciej Mrugula, Priya Kumthekar, Kristin Swanson
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Brain tumor related epilepsy (BTE) is a major co-morbidity in patients with glioma. It is difficult to determine whether the use of anti-epileptic drugs is necessary. We attempted to build a machine-learning model to predict the probability of seizure presentation (SP) with glioma. METHODS We trained a random forest classifier using the following variables: volumetric data of pre-treatment MR images (T1Gd and T2-FLAIR sequences), patient demographics (age; sex), and measurements of tumor proliferation (log(ρ)), invasiveness (log(D)) and their relative ratio (log(ρ/D)). Our cohort consisted of 221 patients total. Using an 80-20 ratio, we used 176 patients (76 SP, 100 nSP) for training and the remaining 45 patients (19 SP, 26 nSP) were used for testing. We also trained on male-only and female-only cohorts to evaluate any sex differences in prediction. For training, 108 males (53 SP, 55 nSP) were used and 28 for testing (14 SP, 14 nSP). We used 72 females (21 SP, 49 nSP) for training and 15 (7 SP, 8 nSP) for testing. We corrected for class imbalance in the female cohort before training. Using 10-fold cross-validation and a separate testing set, we measured performance by ROC curve (AUC), accuracy, sensitivity, and specificity of predictions (average of folds in cross validation). RESULTS The female model achieved the highest AUC (0.853) followed by the mixed model (0.726) and the male model (0.651). In the validation set, the accuracy/sensitivity/specificity of the three cohorts were as follows: mixed (0.726/0.696/0.750), female (0.853/0.830/0.875), and male (0.651/0.577/0.722). The performance of the testing set, in terms of accuracy/sensitivity/specificity were: mixed (0.733/0.74/0.73), female (0.8/0.57/1), and male (0.714/0.64/0.79). CONCLUSION We found a negative correlation between seizure probability and size and invasiveness of tumors. Our model shows promising performance on testing set data. Further cohort studies and training is warranted.
EPID-34. GEODEMOGRAPHIC CLASSIFICATION OF GLIOBLASTOMA RISK IN A RURAL HOSPITAL SYSTEM: RELATIONSHIP TO TUMOR INCIDENCE AND OVERALL SURVIVAL
Authors: Ali Haadi, Justin Kosman, Shane Bross, Jesse Manikowski, Bradley Hinger, Andrew Conger, Joseph Vadakara, Na Tosha Gatson
Journal: Neuro-Oncology (2019)

Abstract In 2019, a projected 86,000 persons in the US will be diagnosed with a primary brain tumor, with an estimated prevalence of 700,000. Glioblastoma (GBM) is the deadliest and most common of these tumors in adults with an overall survival ~15 months. Exposure to ionizing radiation is the single known environmental risk factor for GBM. Most research in the field is directed at treatment and tumor biology/classification. There is growing interest in geodemographics, disease prevention, and measuring quality-survival in GBM. We evaluated 622 GBM patients (2006 to 2018) in Northeastern/Northcentral Pennsylvania treated at one of the nation’s largest rural hospital systems. Each patient was geocoded (plotted longitude/latitude) address at time of diagnosis and we used medical records, projected 2015 Census, and Environmental Protection Agency data to develop risk maps. Preliminary evaluation of overall survival (OS) and incidence related to distance from hospital, age, sex, level of education, insurance, income, and income disparity (Gini coefficient measure of income inequality) was completed. Interestingly, all significant clusters of high GBM incidence lay along water-ways or overlapped with high coal mine reprocessing. Contrary to recent studies, there was no significant sex or distance (0mi to 150mi) impact on survival. However, each age-decile increase resulted in an average 9mo decrease in OS (37mo[&lt; 40yo], 26mo [41-50yo], 17mo [51-60yo], 12mo [61-70yo], and 3mo [&gt;71yo]). Counties with the lowest OS shared geodemographic characteristics such as fewer insured and lower incomes (low income inequality), and counties with more college educated persons had longer survival. Counties with higher GBM incidences had better insured percentages, lower incomes (high income inequality), and large polarity between high school uneducated and college educated persons. Rural populations potentially demonstrate unique geodemographic characteristics that might better predict disease outcomes. Studies in this area could influence improvements in public policy and prevention-focused health literacy opportunities.
EPID-30. A TWITTER-BASED NETWORK ANALYSIS OF BRAIN TUMOR SOCIAL MEDIA (#BTSM)
Authors: Josemari Feliciano, Liz Salmi, Charlie Blotner, Adam Hayden, Edjah Nduom, Bethany Kwan, Matthew Katz, Elizabeth Claus
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The Brain Tumor Social Media (#BTSM) Twitter hashtag was founded in February 2012 as a disease-specific hashtag for brain tumor patients. To understand #BTSM’s role as a patient support system we describe user descriptors, growth, interaction, and content sharing. METHODS We analyzed all tweets containing #BTSM from 2012 to 2018 using the Symplur Signals platform to obtain data and to describe Symplur-defined user categories, tweet content, and trends in use over time. We created a network plot with all publicly-available retweets involving #BTSM in 2018 to visualize key stakeholders and their connections to other users. RESULTS From 2012 to 2018, 59764 unique users participated in #BTSM, amassing 298904 tweets. The yearly volume of #BTSM tweets increased by 264% from 2012 to 2018 with #BTSM constantly trending in the top 15 list of disease hashtags, as well the top 15 list of tweet chats. Patient advocates generated the most #BTSM tweets (33.0%) while advocacy groups, researchers, caregivers and doctors, generated 28.8%, 7.0%, 4.6% and 3.9%, respectively. Physician use, although still low, has increased over time. The 2018 network plot of retweets including #BTSM identifies a number of key stakeholders from the patient advocate, patient organization, and medical researcher domains and reveals the extent of their reach to other users. CONCLUSIONS From its start in 2012, #BTSM has grown exponentially over time. We believe its growth suggests its potential as a global source of brain tumor information for patients, advocates, patient organizations as well as healthcare professionals and researchers.
Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM
Authors: Pasquale L. Fedele, Yang Liao, Jianan Gong, Mark van Delft, Michael S.Y. Low, Lin Tai, Marco J Herold, Julie Tellier, George Grigoriadis, David C.S. Huang, Wei Shi, Stephen Nutt, Simon Willis
Journal: Blood (2019)
Dissociating neural learning signals in human sign- and goal-trackers
Authors: Daniel J. Schad, Michael A. Rapp, Maria Garbusow, Stephan Nebe, Miriam Sebold, Elisabeth Obst, Christian Sommer, Lorenz Deserno, Milena Rabovsky, Eva Friedel, Nina Romanczuk-Seiferth, Hans-Ulrich Wittchen, Ulrich S. Zimmermann, Henrik Walter, Philipp Sterzer, Michael N. Smolka, Florian Schlagenhauf, Andreas Heinz, Peter Dayan, Quentin J. M. Huys
Journal: Nature Human Behaviour (2019)